Acceleron Announces Plans to Initiate a Phase 2 Trial of ACE-083
Acceleron Pharma Inc, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics
Continue Reading
Acceleron Pharma Inc, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics
Continue ReadingResearch conducted at the Institute of Neurology of University College London (UCL) just published in the Proceedings of the National Academy of Sciences USA has identified a set of novel therapeutic targets for a subtype of Charcot-Marie-Tooth disease (CMT), a human condition that currently has no effective treatments.
Continue ReadingDr Andrew Shevchuk and his team from Imperial College London will investigate how mutations associated with some types of centronuclear myopathy and Charcot-Marie-Tooth disease (CMT)
Continue ReadingImplanting stem-derived Schwann-like cells into mice with Charcot-Marie-Tooth type 1A improved neuron function, leading to better motor activity and nerve […]
Continue ReadingMore than 200 delegates from around the world attended the conference held on 19th and 20th April in Fitzwilliam College, […]
Continue ReadingNantes, France – May 22th, 2018. InFlectis BioScience SAS, a drug discovery company committed to the development of innovative therapeutics […]
Continue ReadingLast Updated: Thursday 24th May, 2018